Knight Therapeutics Inc. (KHTRF)
| Market Cap | 806.58M +88.9% |
| Revenue (ttm) | 396.89M +36.1% |
| Net Income | 11.26M |
| EPS | 0.11 |
| Shares Out | n/a |
| PE Ratio | 73.15 |
| Forward PE | 69.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,900 |
| Open | 8.29 |
| Previous Close | 8.20 |
| Day's Range | 8.29 - 8.30 |
| 52-Week Range | 4.11 - 8.61 |
| Beta | 0.02 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Knight Therapeutics
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ... [Read more]
News
What Knight Therapeutics (GUD) Said on Its Q3 Earnings Call
Knight Therapeutics TSE: GUD raised its 2026 revenue and adjusted EBITDA outlook after reporting third-quarter growth driven by its promoted products and launches in Canada and Latin America.
Knight Therapeutics price target raised to C$13 from C$11 at RBC Capital
RBC Capital raised the firm’s price target on Knight Therapeutics (KHTRF) to C$13 from C$11 and keeps an Outperform rating on the shares.
Knight Therapeutics price target raised to C$12.75 from C$12.25 at Stifel
Stifel raised the firm’s price target on Knight Therapeutics (KHTRF) to C$12.75 from C$12.25 and keeps a Buy rating on the shares.
Knight Therapeutics price target raised to C$12.75 from C$11 at Canaccord
Canaccord raised the firm’s price target on Knight Therapeutics (KHTRF) to C$12.75 from C$11 and keeps a Buy rating on the shares.
Knight Therapeutics Inc. Q3 Loss Narrows
(RTTNews) - Knight Therapeutics Inc. (GUD.TO) announced Loss for third quarter of -C$2.68 million
Knight Therapeutics Earnings Call Transcript: Q3 2026
9M revenue reached CAD 430M and adjusted EBITDA exceeded CAD 76M, prompting higher FY26 guidance. Pipeline and launch-product peak revenue potential rose to over CAD 300M, while Brazilian AmBisome generics pose a headwind from 2027.
Knight Therapeutics Earnings release: Q3 2026
Knight Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Knight Therapeutics Report: Q3 2026
Knight Therapeutics published a report on November 5, 2026 containing material business information for investors and shareholders.
Knight Therapeutics MD&A: Q3 2026
Knight Therapeutics filed a regulatory document on November 5, 2026 disclosing important business information.
Notice of Knight Therapeutics’ Third Quarter 2026 Results Conference Call
MONTREAL, Oct. 29, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) pharmaceutical company, will release its third quarter 2026 financial results on Thurs...
Notice of Knight Therapeutics' Third Quarter 2026 Results Conference Call
MONTREAL, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) pharmaceutical company, will release its third quarter 2026 financial results on Thur...
Knight Therapeutics price target raised to C$12.25 from C$11 at Stifel
Stifel raised the firm’s price target on Knight Therapeutics (KHTRF) to C$12.25 from C$11 and keeps a Buy rating on the shares.
Knight Therapeutics, Kyowa Kirin enter distribution agreement for POTELIGEO
Kyowa Kirin International (KYKOF) announced the signing of an exclusive distribution agreement with Knight Therapeutics (KHTRF) for the distribution of mogamulizumab in select countries in Latin Ameri...
Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America
GALASHIELS & MARLOW, U.K.--(BUSINESS WIRE)--Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribut...
Knight Therapeutics signs exclusive distribution agreement with Kyowa Kirin
Knight Therapeutics (KHTRF) announced the signing of an exclusive distribution agreement with Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin (KYKOF), a Japan-based global specialt...
Knight Therapeutics Enters into Exclusive Distribution Agreement with Kyowa Kirin International for Poteligeo® (Mogamulizumab)
MONTREAL, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the signing of an exclusive distribution agr...
Knight Therapeutics Inc. places No. 345 on The Globe and Mail's eighth annual ranking of Canada's Top Growing Companies
MONTREAL, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 345 on the 2026 Report on Business magazine's ranki...
Knight Therapeutics Announces Regulatory Submission of GEMTESA® in Canada
MONTREAL, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for ...
Knight Therapeutics Announces Launch of WYNZORA® in Canada
MONTREAL, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of WYNZORA®, a uniform white aqueo...
Knight Therapeutics Q2 Earnings Call Highlights
Knight Therapeutics TSE: GUD reported record results for the first six months of 2026 and raised its full-year outlook, citing growth in its promoted products, contributions from recent launches and f...
Knight Therapeutics price target raised to C$11 from C$9.50 at Stifel
Stifel analyst Justin Keywood raised the firm’s price target on Knight Therapeutics (KHTRF) to C$11 from C$9.50 and keeps a Buy rating on the shares.
Knight Therapeutics price target raised to C$11 from C$9.50 at RBC Capital
RBC Capital raised the firm’s price target on Knight Therapeutics (KHTRF) to C$11 from C$9.50 and keeps an Outperform rating on the shares.
Knight Therapeutics Earnings Call Transcript: Q2 2026
Record H1 2026 results with CAD 293M revenue and strong EBITDA growth driven by 17 launches. Guidance raised for 2026, expecting at least 20% revenue growth and 15% EBITDA margin, with continued portfolio expansion and stable cash flows supporting future growth.
Knight Therapeutics Report: Q2 2026
Knight Therapeutics published a report on August 6, 2026 containing material business information for investors and shareholders.
Knight Therapeutics MD&A: Q2 2026
Knight Therapeutics filed a regulatory document on August 6, 2026 disclosing important business information.